MedTrace Logo

Effect of a New Formulation of Torasemide (Prolonged Release)on Myocardial Fibrosis in Patients With Heart Failure.

NCT00409942 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 142

Last updated 2009-07-15

No results posted yet for this study

Summary

Torasemide is a loop diuretic (pyridine-sulfonylurea)with a wide experience in the treatment of oedema associated to heart failure, kidney or liver disease and either in the treatment of arterial hypertension (alone or combined with other anti-hypertensive drugs). It has been developed a new formulation of Torasemide (Torasemide prolonged release).

The aim of this trial is to study the effects of Torasemide prolonged released in comparison with furosemide, in the reduction of myocardial fibrosis in patients with chronic heart failure (Class II-IV of the New York Heart Association Classification.

Conditions

  • Congestive Heart Failure

Interventions

DRUG

Torasemide Prolonged Release

Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months

DRUG

Furosemide

Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months

Sponsors & Collaborators

  • Ferrer Internacional S.A.

    lead INDUSTRY

Principal Investigators

  • Antonio Coca, MD, PhD · Hospital Clinic of Barcelona

  • Manuel Anguita, MD, PhD · Hospital Reina Sofia - Córdoba

  • Eduardo De Teresa, MD, PhD · Hospital Clinico - Málaga

  • Alfonso Castro Beiras, MD, PhD · Hospital Juan Canalejo - Coruña

  • Javier Díez · Centro Investigación Médica Aplicada (CIMA) - Pamplona (Navarra)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00409942 on ClinicalTrials.gov